Menu

Experience

Lila Hope

    • Zai Lab Enters License and Collaboration Agreement with Blueprint Medicines 


    • I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment 


    • CardioKinetix Completes $50 Million Financing 


    • Adamas Pharmaceuticals Initial Public Offering 


    • Ascendis Pharma closes $124 million IPO 


    • Nexvet Biopharma Closes Initial Public Offering 


    • Cour and Takeda Partner to Treat Celiac Disease 


    • Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan 


    • Avidity Biosciences Licensing and Research Collaboration with Eli Lilly 


    • Otsuka $825 Million Collaboration Agreement to Develop Alzheimer's Drug 


    • MyoKardia Collaboration with Sanofi 


    • Portola Pharmaceuticals $140 Million IPO 


    • Rigel Pharmaceuticals License and Supply Agreement with Kissei Pharmaceutical Valued up to $180 Million 


    • Turnstone Biologics License Agreement with AbbVie 


    • Vivo Capital in its Licensing Agreements with Ascendis Pharma 


    • Xyphos Biosciences in its Research Collaboration and License Agreement with Parker Institute for Cancer Immunotherapy 


    • Portola Agrees to Sell to Alexion for $1.41 Billion 


    • Fate Therapeutics Licensing and Platform Collaboration with Janssen Biotech 


    • Zai Lab Product Commercialization Collaboration with Regeneron 


    • Vaxcyte - $288 Million IPO 


    • Genesis MedTech Acquires Drug Device Asset From TriReme Medical 


    • Goldfinch Bio Announces Strategic Collaboration with Gilead 


    • Singapore’s Engine Biosciences Raises $43 Million to Decipher Genetic Codes for New Medicines 


    • Lulu’s – $92 Million IPO 


    • Fate Therapeutics Expansion of Collaboration with ONO Pharmaceutical